Oxymorphone hydrochloride monohydrate | 1415015-79-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: Oxymorphone hydrochloride monohydrate
• 英文别名: (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrate;hydrochloride
• CAS: 1415015-79-0
• 化学式: C17H22ClNO5
• 分子量: 355.8
• InChiKey: VLPORDTVKOPOLC-YNLRGPPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.34
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  71
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• METHOD FOR MAKING ANALGESICS
  申请人：Dung Jen-Sen

  公开号：US20080146601A1

  公开（公告）日：2008-06-19

  Improved analgesic oxymorphone hydrochloride contains less than 10 ppm of alpha, beta unsaturated ketones and pharmaceutical preparations comprising such oxymorphone hydrochloride. The oxymorphone hydrochloride is produced by reducing a starting material oxymorphone hydrochloride using gaseous hydrogen and under specified acidity, solvent system and temperature conditions. A specific polymorph of oxymorphone hydrochloride may be obtained by hydration.

  改进的镇痛药盐酸奥沙莫啡含有少于10 ppm的α，β不饱和酮，并且包括含有这种奥沙莫啡盐酸的制药制剂。奥沙莫啡盐酸是通过使用气态氢和指定的酸度、溶剂体系和温度条件还原起始材料奥沙莫啡盐酸而生产的。通过水合作用可以获得奥沙莫啡盐酸的特定晶型。
• IMPROVED METHOD FOR MAKING ANALGESICS
  申请人：JOHNSON MATTHEY PUBLIC LIMITED COMPANY

  公开号：EP2102213A1

  公开（公告）日：2009-09-23
• CRYSTALLINE, ANHYDROUS FORMS OF OXYMORPHONE HYDROCHLORIDE
  申请人：GRÜNENTHAL GMBH

  公开号：US20140088132A1

  公开（公告）日：2014-03-27

  Crystalline, anhydrous hydrochloride salts of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt and such a salt as a medicament and for the treatment and/or prevention of pain.
• Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof
  申请人：Manfredi Paolo L.

  公开号：US20180214395A1

  公开（公告）日：2018-08-02

  The present invention relates to a method of treating or preventing cellular dysfunction and death caused by genetic, degenerative, toxic, traumatic, ischemic, infectious, neoplastic and inflammatory diseases and aging—and their neurological symptoms and manifestations, which includes administering d-methadone, beta-d-methadol, alpha-l-methadol, beta-l-methadol, alpha-d-methadol, acetylmethadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, beta-d-acetylmethadol, beta-l-acetylmethadol, d-alpha-normethadol, l-alpha normethadol, noracetylmethadol, dinoracetylmethadol, methadol, normethadol, dinormethadol, EDDP, EMDP, d-isomethadone, normethadone, N-methyl-methadone, N-methyl-d-methadone, N-methyl-l-methadone, l-moramide, levopropoxyphene, pharmaceutically acceptable salts, or mixtures thereof, including deuterated and tritium analogues, whether isolated from its enantiomer or synthesized de novo.
• US7851482B2
  申请人：——

  公开号：US7851482B2

  公开（公告）日：2010-12-14